3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
2
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Interventions
Exercise
8
Standard of Care
5
trametinib
3
tislelizumab
3
Radiotherapy
3
Radiosurgery
3
Palliative Care
3
Paclitaxel
3
Gemcitabine
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
cemiplimab
2
Therapeutics
2
Surveys and Questionnaires
2
Resistance Training
2
Oxaliplatin
2
Nivolumab
2
Maintenance
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Cisplatin
2
Carboplatin
2
vedolizumab
1
toripalimab
1
surufatinib
1
sparsentan
1
sintilimab
1
semaglutide
1
posaconazole
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasms
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled